California Will Sell $11 Insulin Pens Starting January 2026

State Also Caps Copays at $35

California is about to change the math for people who depend on insulin to stay alive.

Starting January 1, 2026, the state will sell its own insulin pens under the CalRx label for just $11 each, or $55 for a five-pack.

At the same time, a new law caps what insurance companies can charge for insulin at $35 a month.

For the 3.5 million Californians living with diabetes, the timing could not be better, and what happens next could push the entire country to follow.

CalRx Pens Hit Pharmacies in January

California becomes the first state in the nation to sell its own branded insulin when CalRx pens arrive at pharmacies on January 1, 2026.

The state partnered with Civica Rx, a nonprofit drugmaker, and Biocon Biologics to produce the insulin glargine pens. Pharmacies will pay $45 for a five-pack, and consumers will pay no more than $55.

That works out to about $11 per pen, a fraction of what brand-name insulin costs without discounts or insurance.

SB 40 Caps Copays at $35

Governor Gavin Newsom signed Senate Bill 40 in October 2025, capping insulin cost-sharing at $35 for a 30-day supply.

The cap applies to large group health plans starting January 2026, and individual and small group plans must comply by January 2027.

The law also bans insurers from charging deductibles on insulin and prohibits step therapy, which forces patients to try cheaper drugs first before getting what their doctor prescribed.

Insulin Prices Tripled in a Decade

The average price of insulin in the United States nearly tripled between 2002 and 2013, and kept climbing after that.

A 2021 study found that more than half of what Americans spend on insulin now goes to middlemen like pharmacy benefit managers, wholesalers, and health plans.

The actual cost to manufacture a vial of insulin is estimated at just $2 to $4, but patients without good insurance often pay $300 or more at the pharmacy counter.

1 in 4 Americans Skip Doses

Research from Yale found that one in four people with diabetes have rationed their insulin because of cost. They skip doses, take less than prescribed, or delay buying refills to stretch their supply.

A 2022 national study estimated that 1.3 million Americans rationed insulin in a single year.

The problem hits hardest among people under 65 who do not qualify for Medicare and those without insurance.

Rationing Can Be Deadly

Skipping insulin is not like skipping a vitamin. For people with Type 1 diabetes, going without can trigger diabetic ketoacidosis, a condition where blood sugar spikes and the blood becomes dangerously acidic.

It can lead to coma or death within hours. Families have lost loved ones who rationed insulin after aging off their parents’ insurance or losing coverage between jobs.

Doctors call it a preventable tragedy driven entirely by price.

Three Companies Dominated for Decades

Eli Lilly, Novo Nordisk, and Sanofi control about 90% of the global insulin market. For years, all three raised prices in lockstep, with little competition to push costs down.

Public pressure and new laws finally forced changes in 2023, when all three announced price cuts and $35 copay caps for some patients. But those voluntary programs come with restrictions, and not everyone qualifies.

Civica Rx Is a Nonprofit Drugmaker

Civica Rx was founded in 2018 by health systems and philanthropies to fix broken drug markets. The nonprofit now supplies more than 70 essential medicines to over 1,400 hospitals.

California partnered with Civica in 2023 to develop CalRx insulin, and the state originally committed $50 million to the project.

Civica will also distribute its insulin nationwide, not just in California, giving patients across the country access to the same low-cost option.

No New Prescription Needed

Patients who already take Lantus, the brand-name version of insulin glargine, do not need to visit their doctor to switch to CalRx.

The CalRx pens are interchangeable with Lantus, so pharmacists can substitute them directly. Patients just need to ask.

The insulin works the same way and meets the same FDA standards. The only difference is the label and the price.

29 States Now Cap Insulin Costs

California became the 29th state to pass an insulin copay cap when Newsom signed SB 40.

The caps vary by state, ranging from $25 in some places to $100 in others. New York offers a $0 copay for certain plans.

But California stands alone in also producing its own insulin supply, giving the state more control over price and availability than any law alone could provide.

Medicare Patients Already Have a Cap

The 2022 Inflation Reduction Act capped insulin costs at $35 a month for Medicare beneficiaries, helping about 1. 7 million seniors.

But the law did not cover people with private insurance or those without any coverage at all.

State laws like SB 40 fill that gap for millions more, though some patients still fall through the cracks depending on their plan type and where they live.

California Wants to Expand CalRx

Insulin is just the beginning. Newsom has said he wants to add albuterol, GLP-1 weight loss drugs, and even diapers to the CalRx program.

The state already launched CalRx-branded naloxone, the opioid overdose reversal drug, earlier in 2025.

If the insulin launch succeeds, California could become a model for how states take on drug pricing when the federal government will not.

This article was created with AI assistance and human editing.

Read more from this brand:

• Trump’s Plan Could Kill Nursing Schools, 140 Lawmakers Warn
• Game Over for Trump’s National Guard Deployment in Los Angeles
• California’s sleeping monster, the Cascadia fault could trigger a megaquake and tsunami